Bristol-Myers Squibb (BMY) AI Stock Analysis

2 Followers

Bristol-Myers Squibb

(Six Swiss:BMY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified growth portfolioA broad set of commercially meaningful medicines reduces reliance on any single product and supports more durable revenue expansion. The portfolio’s double-digit growth and multiple billion-dollar contributors provide a stronger base for absorbing individual product declines while funding continued innovation.

Negative Factors

Eliquis exclusivity lossEliquis is a major franchise, so the expected post-exclusivity decline creates a material revenue gap that the newer portfolio must replace. Even with continued U.S. growth, this transition can pressure earnings visibility and increase dependence on successful launches and pipeline execution.

Bristol-Myers Squibb (BMY) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 129.04B
Dividend Yield: 3.71%
Average Volume (3M): ―
Price to Earnings (P/E): 14.0
Beta (1Y): 0.21
Revenue Growth: -2.32%
EPS Growth: 43.09%
Country: Switzerland
Employees: 32,500
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hemato...

Bristol-Myers Squibb Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:2.11%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Management reported 7% total revenue growth, 12% growth in the growth portfolio, strong performance from multiple key brands, raised full-year guidance, substantial cash generation, and several positive late-stage pipeline readouts. The principal challenges were the upcoming Eliquis loss of exclusivity, declines in parts of the legacy portfolio and Opdivo, execution issues for Cobenfy, uncertainty around the higher admilparant dose, and the Zolacel program pause following a fatal event. Highlights significantly outweighed the lowlights.

Positive Updates

Double-Digit Growth in Growth Portfolio

The growth portfolio delivered another quarter of double-digit growth, with sales increasing 12% in the third quarter to $7.7 billion, driven by a broad set of differentiated products.

Negative Updates

Opdivo Revenue Decline

Opdivo revenue decreased 6% year over year to $2.4 billion, primarily reflecting continued conversion to Qvantig in the U.S. and Europe.

Company Guidance

Bristol Myers Squibb increased its full year revenue guidance; its expected non GAAP EPS guidance range for 2026 is now $6.35 to $6.55, and excluding the third quarter acquired in process R&D charges and licensing income of $0.58 per share, the midpoint would have increased by approximately $0.15 per share. The company is maintaining its projections for gross margin, operating expenses, and tax rate, while slightly lowering the expense level on its other income and expense line; total legacy portfolio revenue decrease is now expected to be between 3% to 5%, while Eliquis full year revenue growth is expected to be 20% to 25%. For 2027, Eliquis is expected to have a $1.5 billion to $2 billion step down, and the strategic productivity initiative is on track to achieve $2 billion worth of efficiencies by the end of 27; the company also expects physicians to convert at least 30% to 40% of IV business to Qvantig, tracking towards the higher end of that range.

Bristol-Myers Squibb Risk Analysis

Bristol-Myers Squibb disclosed 23 risk factors in its most recent earnings report. Bristol-Myers Squibb reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Bristol-Myers Squibb Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:BMY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	44.28	83.65%	0.49%	45.51%	50.48%
AMGN	75Outperform	$258.68B	26.48	85.59%	2.16%	8.60%	33.48%
NVS	72Outperform	$300.78B	31.59	24.24%	2.93%	1.64%	-28.72%
ABBV	71Outperform	$521.15B	49.44	-202.50%	2.40%	10.68%	338.08%
MRK	63Neutral	$370.96B	149.94	5.29%	2.31%	5.21%	-86.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CH:BMY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:BMY	Bristol-Myers Squibb Company	51.41	-0.65	-1.25%
AMGN	Amgen Inc	460.42	145.50	46.20%
LLY	Eli Lilly And Company	1354.00	393.42	40.96%
MRK	Merck & Company	146.73	62.45	74.11%
NVS	Novartis AG	162.55	37.79	30.29%
ABBV	Abbvie	291.31	78.96	37.18%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bristol-Myers Squibb AI Stock Analysis